Magís-Rodríguez C, Marín-Navarrete R, García-Juárez I

Idioma: Ingles.
Referencias bibliográficas: 14
Paginas: 147-148
Archivo PDF: 102.77 Kb.

FRAGMENTO

Injecting-drug use is present in 179 of 206 countries worldwide, with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) prevalence of 17.8% and 52.3%, respectively, among the 15.6 million people who inject drugs (PWIDs) (Degenhardt et al., 2017; Platt et al., 2016). This epidemic produces a high impact on global public health by increasing days lost associated to disability, morbidity, and mortality (Degenhardt et al., 2017).
For that reason, international recommendations point out that the integration of comprehensive programs for harm reduction in PWIDs with diverse strategies at multiple levels of action increase success. Recommended strategies include: a) needle/syringe programs; b) opioid replacement therapy; c) HIV testing and counseling; d) HIV treatment and care; e) condom programming; f) behavioral interventions; g) prevention and management of viral hepatitis, tuberculosis, and mental health conditions; h) sexual and reproductive health interventions; i) provision of naloxone and training in overdose prevention for the PWIDs (Stancliff, Phillips, Maghsoudi, & Joseph, 2015); and j) drug consumption rooms (European Monitoring Centre for Drugs and Drug Addiction, 2018). Despite the impact of injected drugs worldwide, effective harm reduction programs to prevent their spread are limited in many countries (Wilson, Donald, Shattock, Wilson, & Fraser-Hurt, 2015).

REFERENCIAS (EN ESTE ARTÍCULO)

1. Comisión Nacional contra las Adicciones (CONADIC). (2017). Observatorio Mexicano de Drogas: Informe sobre consumo de drogas inyectables 2017. Retrieved from: https://www.gob.mx/salud/conadic/acciones-y-programas/ observatorio-mexicano-de-drogas-omd

2. Degenhardt, L., Peacock, A., Colledge, S., Leung, J., Grebely, J., Vickerman, P., … Larney, S. (2017). Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. The Lancet Global Health, 5(12), e1192-e1207. doi: 10.1016/S2214-109X(17)30375-3

3. European Monitoring Centre for Drugs and Drug Addiction. (2018). Drug consumption rooms: an overview of provision and evidence (Perspectives on drugs). www. emcdda.europa.eu. Retrieved from: http://www.emcdda.europa.eu/publications/ pods/drug-consumption-rooms_en (Access date: September 4, 2019)

4. Fleiz-Bautista, C., Domínguez-García, M., Villatoro-Velázquez, J. A., Vázquez- Quiroz, F., Zafra-Mora, E., Sánchez-Ramos, R., ... Medina-Mora M. E. (2019). Cuqueando la Chiva: Contextos del consumo de heroína en la frontera norte de México. Ciudad de México, México: Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz. ISBN: 978-607-98474-0-1

5. Horyniak, D., Wagner, K. D., Armenta, R. F., Cuevas-Mota, J., Hendrickson, E., & Garfein, R. S. (2017). Cross-border injection drug use and HIV and hepatitis C virus seropositivity among people who inject drugs in San Diego, California. International Journal of Drug Policy, 47, 9-17. doi: 10.1016/J. DRUGPO.2017.06.006

6. Magis-Rodríguez, C., García-Sánchez, J. A., & Marín-Navarrete, R. (2018). Harm reduction among people who inject drugs in Mexico. Salud Mental, 41(4), 153- 156. doi: 10.17711/SM.0185-3325.2018.023

7. Nápoles, T. M., Batchelder, A. W., Lin, A., Moran, L., Johnson, M. O., Shumway, M., … Riley, E. D. (2019). HCV treatment barriers among HIV/HCV coinfected patients in the US: a qualitative study to understand low uptake among marginalized populations in the DAA era. Journal of Public Health, fdz045. doi: 10.1093/pubmed/fdz045

8. Noe, M. H., Grewal, S. K., Shin, D. B., Ogdie, A., Takeshita, J., & Gelfand, J. M. (2017). Increased prevalence of HCV and hepatic decompensation in adults with psoriasis: a population-based study in the United Kingdom. Journal of the European Academy of Dermatology and Venereology, 31(10), 1674-1680. doi: 10.1111/jdv.14310

9. Platt, L., Easterbrook, P., Gower, E., McDonald, B., Sabin, K., McGowan, C., … Vickerman, P. (2016). Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. The Lancet Infectious Diseases, 16(7), 797-808. doi: 10.1016/S1473-3099(15)00485-5

10. Salmon-Ceron, D., Arends, J. E., Leoni, C., Solas, C., & Peytavin, G. (2019). HIV/ HCV Coinfection: Current Challenges. In: Viral Hepatitis: Chronic Hepatitis C (pp. 141-157). Cham: Springer International Publishing. doi: 10.1007/978- 3-030-03757-4_7

11. Stancliff, S., Phillips, B. W., Maghsoudi, N., & Joseph, H. (2015). Harm reduction: Front line public health. Journal of Addictive Diseases, 34(2-3), 206-219. doi: 10.1080/10550887.2015.1059651

12. Valenzuela-Lara, M., Ponce-Ramos, M., Ruiz-Herrera, K., & López-González, A. (2019). Impact of funding harm reduction programs for people who inject drugs in Mexico. Salud Mental, 42(4), 157-163. doi: 10.17711/SM.0185- 3325.2019.021

13. Wilson, D. P., Donald, B., Shattock, A. J., Wilson, D., & Fraser-Hurt, N. (2015). The cost-effectiveness of harm reduction. International Journal of Drug Policy, 26(Suppl 1), S5-S11. doi: 10.1016/J.DRUGPO.2014.11.007

14. Xue, W., Liu, K., Qiu, K., Shen, Y., Pan, Z., Hu, P., … Ren, H. (2019). A systematic review with meta-analysis: Is ribavirin necessary in sofosbuvir-based directacting antiviral therapies for patients with HCV recurrence after liver transplantation? International Journal of Infectious Diseases, 83, 56-63. doi: 10.1016/J.IJID.2019.03.038